On Friday, Recordati, the Italian pharma group, said it would buy from Sanofi (NASDAQ: SNY) the global rights to a
1 year ago
Sanofi (NASDAQ: SNY) has received two separate bids from private equity firms for its consumer health unit, which could be
NEW YORK – Sanofi’s (NASDAQ: SNY) chief executive, Paul Hudson, said in an interview on Monday that the company is
On Friday, the U.S. Food and Drug Administration said it has approved the use of a drug combination along with
FRANKFURT – On Friday, Sanofi (NASDAQ: SNY) said that its multiple sclerosis drug candidate was shown to delay the worsening
Sanofi’s (NASDAQ: SNY) most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat
On Thursday, Sanofi (NASDAQ: SNY) raised its full-year profit outlook after strong demand for blockbuster asthma drug Dupixent and better-than-expected
HYDERABAD – French drugmaker Sanofi (NASDAQ: SNY) plans to invest 400 million euros ($437.24 million) in its global capacity center
2 years ago
Bpifrance Executive Director Jose Gonzalo said that the public investment bank is considering a potential investment in Sanofi’s (NASDAQ: SNY)
On Wednesday, Sanofi (NASDAQ: SNY) and partner Regeneron (NASDAQ: REGN) won European Union approval for wider use of their Dupixent
BERLIN – French drugmaker Sanofi (NASDAQ: SNY) is nearing a decision to invest between 1.3 billion and 1.5 billion euros
